Clinical implications of genetic polymorphisms on stomach cancer drug therapy.
Toffoli
G
G
Experimental and Clinical Pharmacology, CRO-National Cancer Institute, Aviano, Italy. gtoffoli@cro.it
Cecchin
E
E
D000970:Antineoplastic Agents / Q000493:pharmacokinetics / Q000627:therapeutic use*; D001711:Biotransformation / Q000235:genetics; D005472:Fluorouracil / Q000627:therapeutic use; D015971:Gene Expression Regulation, Enzymologic; D015972:Gene Expression Regulation, Neoplastic; D005838:Genotype; D006801:Humans; D018579:Patient Selection; D020641:Polymorphism, Single Nucleotide; D013274:Stomach Neoplasms / Q000188:drug therapy* / Q000201:enzymology / Q000235:genetics*; D016896:Treatment Outcome
D000970:Antineoplastic Agents; D005472:Fluorouracil